Page 9 - ஆர்க்டரஸ் சிகிச்சை ஹோல்டிங்ஸ் இன்க் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Arcturus Therapeutics Received Approval from Singapore Health Sciences Authority to Proceed with Phase 2 Study of ARCT-021 (LUNAR-COV19) Vaccine Candidate and Provides New and Updated Clinical and Preclinical Data

Arcturus Therapeutics Received Approval from Singapore Health Sciences Authority to Proceed with Phase 2 Study of ARCT-021 (LUNAR-COV19) Vaccine Candidate and Provides New and Updated Clinical and Preclinical Data
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

United statesSan diegoEng eongCarlo tanziSteve hughesNeda safarzadehUltragenyx pharmaceutical incInfectious diseases programmeJanssen pharmaceuticals incArcturus therapeutics holdings incCystic fibrosis foundationJanssen pharmaceutical companies of johnsonTakeda pharmaceutical companySingapore health sciences authoritySynthetic genomics incMrna technology

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), (ABCL) - The Daily Biotech Pulse: FDA Nod For Amphastar s Generic Glucagon, Arcturus Sinks On Vaccine Data, Decision Day For Osmotica

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), (ABCL) - The Daily Biotech Pulse: FDA Nod For Amphastar s Generic Glucagon, Arcturus Sinks On Vaccine Data, Decision Day For Osmotica
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.

Hong kongKeith grossmanChristopher peetzWilliam liangNovo nordiskZai labVirios therapeuticsGilead sciences incAprea therapeutics incLiquidia corpZai lab licensed ovarian cancer drug eligibleZai lab ltdAlkermes plcBristol myers squibb coInhibikase therapeutics incEuropean medicines agency for ozempic

Mid-Day Market Update: Crude Oil Rises 1%; Arcturus Therapeutics Shares Drop

Mid-Day Market Update: Crude Oil Rises 1%; Arcturus Therapeutics Shares Drop
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.

United kingdomCity ofRaymond jamesJohns hopkins universitySecurity instruments incInmune bio incAerocentury corpTechnical communicationsSenate minority leader chuck schumerBionano genomics incMonaker group incArcturus therapeutics holdings incCaesarstone ltdHc wainwright coTechnical communications corporationMonaker group

Arcturus Therapeutics shares slide 37% in premarket after COVID vaccine data are deemed underwhelming

Arcturus Therapeutics shares slide 37% in premarket after COVID vaccine data are deemed underwhelming
marketwatch.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketwatch.com Daily Mail and Mail on Sunday newspapers.

San diegoUnited statesStephen seedhouseRaymond jamesSingapore health sciences authorityPfizer incModerna incDrug administrationArcturus therapeutics holdings incArcturus therapeutics holdingsMarket performசான் டியாகோஒன்றுபட்டது மாநிலங்களில்ரேமஂட் ஜேம்ஸ்சிங்கப்பூர் ஆரோக்கியம் அறிவியல் அதிகாரம்ஃபைசர் இன்க்

Arcturus Therapeutics Receives Approval from Health Sciences Authority to Proceed with Phase 2 Study of Vaccine Candidate

Posted on 3643 Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT)reported approval from the Singapore Health Sciences Authority to commence its Phase 2 clinical study of its vaccine candidate ARCT-021. The study will utilize its favorable phase ½ study results, including supportive preclinical data. “We are pleased to advance ARCT-021 into a Phase 2 study based upon our promising Phase 1/2 data, which continues to support the potential for Arcturus’ STARR™ self-replicating mRNA technology to provide a highly effective, and differentiated clinical profile, including a single dose regimen,” said Steve Hughes, M.D., Chief Development Officer of Arcturus. “The Phase 2 study will enable selection of the optimal ARCT-021 vaccination regimen for Phase 3 registrational studies. We look forward to obtaining interim Phase 2 data in early 2021 providing support for the anticipated initiation of a global Phase 3 stud

Eng eongSteve hughesSingapore health sciences authorityInfectious diseases programmeArcturus therapeutics holdings incArcturus therapeutics holdingsChief development officerOoi eng eongEmerging infectious diseases programmeVaccine platform scientific advisoryஸ்டீவ் ஹக்ஸ்சிங்கப்பூர் ஆரோக்கியம் அறிவியல் அதிகாரம்தொற்று நோய்கள் ப்ரோக்ராம்ஆர்க்டரஸ் சிகிச்சை ஹோல்டிங்ஸ் இன்க்ஆர்க்டரஸ் சிகிச்சை ஹோல்டிங்ஸ்தலைமை வளர்ச்சி அதிகாரி